Lilly, METiS ink AI-driven drug delivery deal worth up to $1.1B
JHVEPhoto/iStock Editorial via Getty Images
Chinese biotech company METiS TechBio (MTBOY) has announced a partnership with Eli Lilly (LLY) to develop next-gen drug delivery technologies using artificial intelligence in a deal worth up to $1.1B.
As part of the collaboration, the companies will develop novel lipid nanoparticle (LNP)-based drug delivery solutions leveraging METiS’ AI-driven ionizable lipid discovery and optimization platform, AiLNP.
LNP technology, a key delivery mechanism used in messenger-RNA-based vaccines such as Moderna’s (MRNA) Spikevax, enables tissue-specific distribution of therapeutics effectively.
The partnership, which extends across multiple therapeutic areas, will combine Indiana-based Lilly’s (LLY) expertise in drug discovery, development, and commercialization with the AiLNP AI-powered platform, Chris Lai, CEO of METiS, said in a statement on Monday.
In exchange, the Hong Kong-listed company will receive an upfront payment valued at low double-digit millions of U.S. dollars in addition to development, regulatory, and commercial milestone payments worth up to $1.1B.
METiS is also entitled to single-digit tiered royalties based on annual net sales of products resulting from the deal.
Recommended For You
Create Your Free Account to Keep Reading
Get the confidence to navigate an uncertain market with free breaking news and stock alerts.
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.